Advertisement
Home Day 1

Day 1

CAR T-Cell Treatment Associated with Reduced Health Care Use, Costs After Infusion

A study presented at the 2020 ASH Annual Meeting found that chimeric antigen receptor (CAR) T-cell therapy resulted in less health care...

Inpatient Cancer Deaths Associated with Increased Costs

Despite a decrease in the percentage of inpatient deaths over time, more than 40% of patients with multiple myeloma (MM) die in...

Study Compares Costs of Adding Selinexor to Bortezomib and Dexamethasone for Patients with Multiple...

Results from the phase III BOSTON clinical trial reported that once-weekly selinexor, bortezomib, and dexamethasone (SVd) significantly prolonged progression-free survival for patients...

CRS, Neurologic Events Increase Costs, Health Care Utilization in Patients Receiving CAR T-Cell Therapy...

Idecabtagene vicleucel (ide-cel) is a chimeric antigen receptor (CAR) T-cell therapy in development for patients with relapsed/refractory multiple myeloma (MM) who are...
Advertisement
Advertisement